HumanOptics has received Food and Drug Administration (FDA) approval to market its artificial iris in the US. The German start-up's device can be used in adults and children whose iris is missing due to injury or rare genetic disorder aniridia, which occurs in about one in 50,000 to 100,000 newborns worldwide. In a press release, Human Optics' CEO Dr. Michael Scheufele said that his company was "excited by this new technology for people with eye disease. It was shown to be safe and effective in a clinical trial of 389 adults and children with aniridia or other iris defects. " It was shown to be safe and effective in a clinical trial of 389 patients.
HumanOptics has received Food and Drug Administration (FDA) approval to market its artificial iris in the US. The German start-up's device can be used in adults and children whose iris is missing due to injury or rare genetic disorder aniridia, which occurs in about one in 50,000 to 100,000 newborns worldwide. In a press release, Human Optics' CEO Dr. Michael Scheufele said that his company was "excited by this new technology for people with eye disease." It was shown to be safe and effective in a clinical trial of 389 patients.